Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Photo: Justin Sullivan/Getty Images
The health care world was aflutter yesterday over a report in the industry publication Reorg Research that says antitrust officials at the Department of Justice won’t challenge CVS Health’s $69 billion acquisition of Aetna, and may send an approval memo as soon as the end of this month.
Why it matters: If this merger does indeed proceed, CVS would soon absorb a gigantic health insurance business into its pharmacies, pharmacy benefit manager and clinics, inevitably affecting the health care and pocketbooks of millions of Americans.
Between the lines: The DOJ may feel a little burned from losing the AT&T-Time Warner merger case, which paved a pathway for more approvals of large vertical mergers like CVS and Aetna. But this report was news to both CVS and Aetna.
- A CVS spokesperson said the pharmacy giant doesn’t “comment on market rumors,” and an Aetna spokesperson said the company had no comment.
Yes, but: CVS and Aetna have a lot of overlap with their Medicare prescription drug plans. It’s very difficult to believe the government won’t demand some level of divestiture of those plans, at a minimum.